Plus Therapeutics Secures Elevance Health National Coverage for CNSide CNS Cancer Test

Key Facts

1CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national agreement with Elevance Health to provide the CNSide CSF TCE assay effective May 1, 2026.

2The agreement covers approximately 45.4 million people, bringing total contracted coverage for the CNSide assay to 126 million people.

3The CNSide assay demonstrated high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases across over 11,000 tests since 2020.

In a move that underscores the growing role of precision diagnostics in oncology, CNSide Diagnostics, a subsidiary of Plus Therapeutics, announced a national agreement with Elevance Health to provide the CNSide CSF TCE assay effective May 1, 2026. According to a company statement, the pact covers approximately 45.4 million additional lives, bringing total contracted coverage for the test to 126 million people. The test demonstrated high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases across more than 11,000 tests since 2020.

The expanded coverage comes amid rising demand for molecular diagnostics in precision medicine. CNSide is designed to diagnose and manage leptomeningeal metastases from CNS cancer, enabling early detection and guided therapy. In trading, ELV (Elevance Health) closed at $384.00 on June 24, 2026, while PSTV (Plus Therapeutics) closed at $4.08 on June 23, 2026, per market data. The agreement highlights Elevance Health's commitment to broadening access to specialized care.

Investors are watching whether Plus Therapeutics can leverage the national coverage to accelerate adoption in the U.S. market. With PSTV closing at $4.08, further negotiations with other insurers or additional utilization data could act as positive catalysts for the stock. The company's next quarterly performance will be a key indicator of the commercial strategy's success.